These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 8548729)

  • 1. Fluvoxamine and mandibular dystonia.
    Chong SA
    Can J Psychiatry; 1995 Sep; 40(7):430-1. PubMed ID: 8548729
    [No Abstract]   [Full Text] [Related]  

  • 2. Complex movement disorder associated with fluvoxamine.
    Bronner IM; Vanneste JA
    Mov Disord; 1998 Sep; 13(5):848-50. PubMed ID: 9756160
    [No Abstract]   [Full Text] [Related]  

  • 3. Toxicity with selective serotonin reuptake inhibitors.
    Solomons K; Gooch S; Wong A
    Am J Psychiatry; 2005 Jun; 162(6):1225. PubMed ID: 15930079
    [No Abstract]   [Full Text] [Related]  

  • 4. An alert to extrapyramidal side-effects from SSRIs.
    Hoaken PC
    Can J Psychiatry; 1995 Feb; 40(1):51. PubMed ID: 7874680
    [No Abstract]   [Full Text] [Related]  

  • 5. SSRIs and mammoplasia.
    Marcus P
    Am J Psychiatry; 2001 Jun; 158(6):967. PubMed ID: 11384918
    [No Abstract]   [Full Text] [Related]  

  • 6. Antisocial ideation and activities precipitated by the administration of SSRIs.
    Glancy GD
    Can J Psychiatry; 1993 Dec; 38(10):695. PubMed ID: 8313312
    [No Abstract]   [Full Text] [Related]  

  • 7. SSRI-induced parkinsonism may be an early sign of future Parkinson's disease.
    Gönül AS; Aksu M
    J Clin Psychiatry; 1999 Jun; 60(6):410. PubMed ID: 10401924
    [No Abstract]   [Full Text] [Related]  

  • 8. Quetiapine-fluvoxamine combination during pregnancy and while breastfeeding.
    Gentile S
    Arch Womens Ment Health; 2006 May; 9(3):158-9. PubMed ID: 16683078
    [No Abstract]   [Full Text] [Related]  

  • 9. Movement disorders associated with fluvoxamine.
    Lenti C
    J Am Acad Child Adolesc Psychiatry; 1999 Aug; 38(8):942-3. PubMed ID: 10434483
    [No Abstract]   [Full Text] [Related]  

  • 10. Fluvoxamine. A review of its safety profile in world-wide studies.
    Wagner W; Zaborny BA; Gray TE
    Int Clin Psychopharmacol; 1994; 9(4):223-7. PubMed ID: 7868844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute dystonia associated with fluvoxamine-metoclopramide.
    Palop V; Jimenez MJ; Catalán C; Martínez-Mir I
    Ann Pharmacother; 1999 Mar; 33(3):382. PubMed ID: 10200869
    [No Abstract]   [Full Text] [Related]  

  • 12. Dyskinesia associated with fluvoxamine.
    Arya DK; Szabadi E
    J Clin Psychopharmacol; 1993 Oct; 13(5):365-6. PubMed ID: 8227498
    [No Abstract]   [Full Text] [Related]  

  • 13. Fluvoxamine induced oculogyric dystonia and manic switch in a patient with obsessive compulsive disorder.
    Tikka SK; Garg S; Das B
    Indian J Pharmacol; 2013; 45(5):532-3. PubMed ID: 24130396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suicidal risk during controlled clinical investigations of fluvoxamine.
    Letizia C; Kapik B; Flanders WD
    J Clin Psychiatry; 1996 Sep; 57(9):415-21. PubMed ID: 9746450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Manic-switch induced by fluvoxamine in abstinent pure methamphetamine abusers.
    Won M; Minabe Y; Sekine Y; Takei N; Kondo N; Mori N
    J Psychiatry Neurosci; 2003 Mar; 28(2):134-5. PubMed ID: 12670131
    [No Abstract]   [Full Text] [Related]  

  • 16. If a patient does not respond to a full dose of fluvoxamine for at least 12 weeks, what alternatives should be considered?
    Ravindran AV
    J Psychiatry Neurosci; 1998 Mar; 23(2):136. PubMed ID: 9549254
    [No Abstract]   [Full Text] [Related]  

  • 17. Efficacy and tolerability of citalopram in comparison with fluvoxamine in depressed outpatients: a double-blind, multicentre study. The LUCIFER Group.
    Haffmans PM; Timmerman L; Hoogduin CA
    Int Clin Psychopharmacol; 1996 Sep; 11(3):157-64. PubMed ID: 8923094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluvoxamine and clomipramine in depressed hospitalised patients: results from a randomised, double-blind study.
    Ottevanger EA
    Encephale; 1995; 21(4):317-21. PubMed ID: 7588171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluvoxamine open-label treatment of adolescent inpatients with obsessive-compulsive disorder or depression.
    Apter A; Ratzoni G; King RA; Weizman A; Iancu I; Binder M; Riddle MA
    J Am Acad Child Adolesc Psychiatry; 1994; 33(3):342-8. PubMed ID: 8169178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ecchymoses as an adverse effect of fluvoxamine treatment in an adolescent girl.
    Vlatka BM; Branka AM; Branimir M
    Gen Hosp Psychiatry; 2010; 32(4):e9-e10. PubMed ID: 20633737
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.